These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
358 related articles for article (PubMed ID: 31901668)
1. The efficacy of perampanel in young children with drug-resistant epilepsy. Chang FM; Fan PC; Weng WC; Chang CH; Lee WT Seizure; 2020 Feb; 75():82-86. PubMed ID: 31901668 [TBL] [Abstract][Full Text] [Related]
2. Clinical profiles associated with serum perampanel concentrations in children with refractory epilepsy. Ishikawa N; Tateishi Y; Tani H; Kobayashi Y; Kobayashi M Epilepsy Behav; 2019 May; 94():82-86. PubMed ID: 30897534 [TBL] [Abstract][Full Text] [Related]
3. Tolerability and efficacy of perampanel in children with refractory epilepsy. Heyman E; Lahat E; Levin N; Epstein O; Lazinger M; Berkovitch M; Gandelman-Marton R Dev Med Child Neurol; 2017 Apr; 59(4):441-444. PubMed ID: 27935018 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness and tolerability of Perampanel in children, adolescents and young adults with refractory epilepsy: A UK national multicentre study. Swiderska N; Tan HJ; Rajai A; Silwal A; Desurkar A; Martland T Seizure; 2017 Nov; 52():63-70. PubMed ID: 28992560 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and serum concentrations of perampanel for treatment of drug-resistant epilepsy in children, adolescents, and young adults: comparison of patients younger and older than 12 years. Ikemoto S; Hamano SI; Hirata Y; Matsuura R; Koichihara R Seizure; 2019 Dec; 73():75-78. PubMed ID: 31759296 [TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of mono- and add-on perampanel in pediatric patients with epilepsy: Experience from a single-center retrospective study. Li Y; Guo HL; Hu YH; Wang J; Zhang YY; Huang J; Xu J; Chen J; Lu XP; Chen F Epilepsia Open; 2024 Feb; 9(1):268-277. PubMed ID: 37943144 [TBL] [Abstract][Full Text] [Related]
7. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies-An Italian observational multicenter study. De Liso P; Vigevano F; Specchio N; De Palma L; Bonanni P; Osanni E; Coppola G; Parisi P; Grosso S; Verrotti A; Spalice A; Nicita F; Zamponi N; Siliquini S; Giordano L; Martelli P; Guerrini R; Rosati A; Ilvento L; Belcastro V; Striano P; Vari MS; Capovilla G; Beccaria F; Bruni O; Luchetti A; Gobbi G; Russo A; Pruna D; Tozzi AE; Cusmai R Epilepsy Res; 2016 Nov; 127():93-100. PubMed ID: 27568598 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of adjuvant perampanel: an Australian multicenter real-world observational study in refractory focal and generalized epilepsy syndromes. Sagar P; Wawryk O; Vogrin S; Whitham E; Kiley M; Frasca J; Carne R; Seneviratne U; Cook MJ; Lawn N; Nikpour A; D'Souza WJ Epilepsy Behav; 2021 Jun; 119():107935. PubMed ID: 33930626 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of perampanel in children and adolescents with pharmacoresistant epilepsy: The first real-world evaluation in Asian pediatric neurology clinics. Lin KL; Lin JJ; Chou ML; Hung PC; Hsieh MY; Chou IJ; Lim SN; Wu T; Wang HS Epilepsy Behav; 2018 Aug; 85():188-194. PubMed ID: 30032806 [TBL] [Abstract][Full Text] [Related]
10. Use of perampanel in children with refractory epilepsy of genetic aetiology. Qu R; Dai Y; Qu X; Li Y; Shao X; Zhou R; Zhu Y; Chen X Epileptic Disord; 2022 Aug; 24(4):687-695. PubMed ID: 35770768 [TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of perampanel in children and adults with various epilepsy syndromes: A single-center postmarketing study. Singh K; Shah YD; Luciano D; Friedman D; Devinsky O; Kothare SV Epilepsy Behav; 2016 Aug; 61():41-45. PubMed ID: 27300147 [TBL] [Abstract][Full Text] [Related]
12. Clinical Experience With Perampanel for Refractory Pediatric Epilepsy in One Canadian Center. Datta AN; Xu Q; Sachedina S; Boelman C; Huh L; Connolly MB J Child Neurol; 2017 Aug; 32(9):834-839. PubMed ID: 28511603 [TBL] [Abstract][Full Text] [Related]
13. Perampanel as adjunctive therapy in highly refractory epilepsies: Real-world data from an Italian tertiary care epilepsy centre. Morano A; Fattouch J; Albini M; Casciato S; Fanella M; Basili LM; Viganò A; Manfredi M; Giallonardo AT; Di Bonaventura C J Neurol Sci; 2018 Jul; 390():67-74. PubMed ID: 29801910 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of perampanel as an adjunct therapy in refractory epilepsy from real-world experience. Chang RS; Lui HKK; Leung YHI; Leung WCY; Yam KK; Wang Y J Neurol Sci; 2019 Oct; 405():116416. PubMed ID: 31445298 [No Abstract] [Full Text] [Related]
15. Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study. Nishida T; Lee SK; Inoue Y; Saeki K; Ishikawa K; Kaneko S Acta Neurol Scand; 2018 Apr; 137(4):392-399. PubMed ID: 29250772 [TBL] [Abstract][Full Text] [Related]
16. Electro-clinical analysis of epilepsy patients with generalized seizures on adjunctive perampanel treatment. Montoya Gutiérrez FJ; Díaz Román M; Cerveró Albert D Epilepsy Res; 2020 Sep; 165():106378. PubMed ID: 32622260 [TBL] [Abstract][Full Text] [Related]
17. A two-year retrospective evaluation of perampanel in patients with highly drug-resistant epilepsy and cognitive impairment. Huber B; Schmid G Epilepsy Behav; 2017 Jan; 66():74-79. PubMed ID: 28038390 [TBL] [Abstract][Full Text] [Related]
18. Perampanel: Does it have broad-spectrum potential? Potschka H; Trinka E Epilepsia; 2019 Mar; 60 Suppl 1():22-36. PubMed ID: 29953584 [TBL] [Abstract][Full Text] [Related]
19. Perampanel: A Review in Drug-Resistant Epilepsy. Frampton JE Drugs; 2015 Sep; 75(14):1657-68. PubMed ID: 26370209 [TBL] [Abstract][Full Text] [Related]
20. Perampanel for the treatment of epilepsy with genetic aetiology: Real-world evidence from the PERMIT Extension study. Delanty N; Mohanraj R; Shankar R; Wehner T; Stephen LJ; D'Souza W; Cappucci S; McMurray R; Sainz-Fuertes R; Villanueva V Epilepsy Res; 2024 May; 202():107339. PubMed ID: 38492461 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]